Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open-label, randomized, multicenter, phase III study
Patients with baseline Hb comprised between 9 and 10.5g/dl will be randomized to receive EPO Alfa 60000 UI/week for at least 12 weeks:
in this trial we will compare the early introduction of EPO alfa to the delayed introduction in lower risk MDS with non RBC transfusion dependent anemia.
At enrollment patients will be randomised in the 2 arms (early and delayed start of EPO alfa).
Treatment Regimen Epoetin alfa 60000 UI/week for at least 12 weeks
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Early onset arm | Experimental | Intervention: early onset of Eprex60000 IU/week , at patient inclusion |
|
| Delayed onset arm | Experimental | Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EPREX | Drug | 60 000 U/week for at least 12 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time to RBC transfusion dependence in non RBC transfusion dependent lower risk MDS patients with anemia with early (at inclusion of the patient) versus delayed onset,( at the threshold chosen for RBC transfusion) of EPO ALFA | RBC transfusion dependence will be defined by requirement of at least transfusions of 2 PRBC within an interval of less than 8 weeks, given for Hb <8g/dl or <9g/dl according to comorbidities and in the absence of other cause of anemia (bleeding, surgery…), taking into account only transfusions given at least 12 weeks after onset of treatment with EPO ALFA. | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Erythroid response (according to IWG 2006 criteria) | Erythroid response (according to IWG 2006 criteria) after 12 weeks of EPO ALFA treatment | 12 weeks |
| response duration to EPO ALFA | response duration to EPO ALFA measured from the date of enrollment until failure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sophie Park, Prof | University Hospital, Grenoble | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chu Amiens | Amiens | France | ||||
| CH Angers |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
randomazed study
Not provided
Not provided
Not provided
Not provided
| 4 years |
| Overall survival | Overall survival measured from the date of enrollment to death or the date of last contact | 4 years |
| Angers |
| 49 000 |
| France |
| CH Avignon | Avignon | 84000 | France |
| Centre Hospitalier de La Cote Basque | Bayonne | 64100 | France |
| Hopital Nord Franche-Comté | Belfort | 90015 | France |
| CHU de Besançon | Besançon | 25030 | France |
| Hopital Avicenne | Bobigny | 9300 | France |
| Hôpital Morvan | Brest | 29609 | France |
| CHU de Caen | Caen | 14033 | France |
| CH de Sevigné | Cesson | 35510 | France |
| CH de Cholet | Cholet | 49325 | France |
| CHU Estaing | Clermont-Ferrand | 63000 | France |
| CHSF Gilles de Corbeil | Corbeil-Essonnes | 91100 | France |
| Hôpital Henri-Mondor | Créteil | 94010 | France |
| CHU de Grenoble | Grenoble | 38043 | France |
| Centre Hospitalier du Mans | Le Mans | 72000 | France |
| Clinique Victor Hugo | Le Mans | 72000 | France |
| Hopital Saint-Vincent de Paul | Lille | 59160 | France |
| CHRU Limoges | Limoges | 87042 | France |
| Centre Hospitalier Lyon Sud | Lyon | 69495 | France |
| IPC | Marseille | 13273 | France |
| Centre Hospitalier du Mont de Marsan | Mont-de-Marsan | 40000 | France |
| CHU de Nantes | Nantes | 44093 | France |
| CHU de Nice | Nice | France |
| Hopital St Louis T4 | Paris | 75475 | France |
| Centre Hospitalier Joffre-Perpignan | Perpignan | 66046 | France |
| Sophie Dimicoli-Salazar | Pessac | 33604 | France |
| CH de Périgueux | Périgueux | 24019 | France |
| CHU de Poitiers | Poitiers | 86021 | France |
| CHR d'Annecy | Pringy | 74374 | France |
| CHRU de Reims | Reims | 51092 | France |
| CHU Pontchaillou | Rennes | 35033 | France |
| Centre Henri Becquerel | Rouen | 76038 | France |
| CH Saint Nazaire | Saint-Nazaire | 44600 | France |
| Centre Hospitalier Universitaire de STRASBOURG | Strasbourg | 67098 | France |
| IUCT Oncopole | Toulouse | 31059 | France |
| CH de Troyes | Troyes | 10003 | France |
| CH Valence | Valence | 26953 | France |
| CHU Brabois | Vandœuvre-lès-Nancy | 54511 | France |
| ID | Term |
|---|---|
| D009190 | Myelodysplastic Syndromes |
| ID | Term |
|---|---|
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068817 | Epoetin Alfa |
| ID | Term |
|---|---|
| D004921 | Erythropoietin |
| D003115 | Colony-Stimulating Factors |
| D006023 | Glycoproteins |
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D016298 | Hematopoietic Cell Growth Factors |
| D016207 | Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011506 | Proteins |
| D001685 | Biological Factors |
Not provided
Not provided